23-Jun-2026 - Zacks ABBV Jumps on Deepening Immunology Portfolio With $10.9B APGE Buyout Shares of AbbVie ABBV rose more than 6% on Monday after the company announced that it entered into a definitive agreement to acquire clinical-stage biotech Apogee Therapeutics APGE for $135.11 per ...
22-Jun-2026 - Seeking Alpha AbbVie's Skyrizi wins EU approval for pediatric plaque psoriasis AbbVie ( ABBV) Tuesday said that the European Commission has approved Skyrizi (risankizumab) for the treatment of children and adolescents six years of age and older with moderate to severe plaque ...
22-Jun-2026 - The Globe and Mail AbbVie (ABBV) Gets a Buy from Wells Fargo In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on AbbVie, with a price target of $260.00. Unlock powerful investing tools and data-driven insights with TipRanks ...
22-Jun-2026 - Yahoo Finance The $11 Billion Reason Abbvie Stock Is Up Today AbbVie stock rallied today on the $10.9 billion acquisition of Apogee Therapeutics. Here’s how you should play ABBV shares at ...
22-Jun-2026 - Barchart The $11 billion reason AbbVie stock is up today AbbVie (ABBV) shares rallied sharply on Monday after the pharmaceutical behemoth announced a definitive agreement to acquire Apogee Therapeutics (APGE) for about $10.9 billion. The all-cash ...
23-Jun-2026 - Zacks ABBV Jumps on Deepening Immunology Portfolio With $10.9B APGE Buyout Shares of AbbVie ABBV rose more than 6% on Monday after the company announced that it entered into a definitive agreement to acquire clinical-stage biotech Apogee Therapeutics APGE for $135.11 per ...
22-Jun-2026 - Seeking Alpha AbbVie's Skyrizi wins EU approval for pediatric plaque psoriasis AbbVie ( ABBV) Tuesday said that the European Commission has approved Skyrizi (risankizumab) for the treatment of children and adolescents six years of age and older with moderate to severe plaque ...
22-Jun-2026 - The Globe and Mail AbbVie (ABBV) Gets a Buy from Wells Fargo In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on AbbVie, with a price target of $260.00. Unlock powerful investing tools and data-driven insights with TipRanks ...
22-Jun-2026 - Yahoo Finance The $11 Billion Reason Abbvie Stock Is Up Today AbbVie stock rallied today on the $10.9 billion acquisition of Apogee Therapeutics. Here’s how you should play ABBV shares at ...
22-Jun-2026 - Barchart The $11 billion reason AbbVie stock is up today AbbVie (ABBV) shares rallied sharply on Monday after the pharmaceutical behemoth announced a definitive agreement to acquire Apogee Therapeutics (APGE) for about $10.9 billion. The all-cash ...
